Filament Health (FH.NEO) expands on their intellectual property portfolio with 20th patent application

Filament Health (FH.NEO) filed their 20th patent application for their research phase programs, including three international Patent Cooperation Treaty (PCT) applications, earlier this week, according to a press release.


The patent includes claims to the processing, extraction and standardization of psychoactive compounds in support of the company’s clinical programs. The company contends that the examiners allowance and acceptance of all the stated claims demonstrates evidence of the patent’s novelty, utility and inventive steps.


“This milestone sets us ahead of industry peers and demonstrates the strength of our IP strategy. Many naturally occurring compounds have great potential to alleviate suffering, and our patent filings cover a range of innovative technologies necessary for transforming the healing power of those compounds into pharmaceutical standardized form,” said Benjamin Lightburn, chief executive officer.


Filament Health is a natural psychedelic drug discovery and extraction tech company into extractions tech commercialization, using its extensive intellectual property portfolio, as well as their in-house good manufacturing practice certified facility and Health Canada issued dealer’s license for psychedelics.

“We will leverage our success in Canada by utilizing the Patent Prosecution Highway (PPH) in the United States and internationally. This will allow Filament to achieve patent issuance more quickly as the PPH uses fast-track examination procedures among participating patent offices such as those in the U.S., Canada and Europe,” said Taran Grey, director of intellectual property.


Filament Health shares climbed by a penny today, and are presently trading at $0.35 on the NEO exchange.

—Joseph Morton

Full disclosure: Filament Health is an equity guru marketing client.

The post Filament Health (FH.NEO) expands on their intellectual property portfolio with 20th patent application appeared first on Equity.Guru.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.